*Muthoot Finance Ltd. -S* | *CMP* Rs. 1321 | *M Cap* Rs. 52998 Cr | *52 W H/L* 1406/703
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Asset quality details are not yet declared
NII came at Rs. 1872.6 Cr vs expectation of Rs. 1887.3 Cr, YoY Rs. 1630.3 Cr, QoQ Rs. 1819.3 Cr
PBP came at Rs. 1360.8 Cr vs expectation of Rs. 1382.6 Cr, YoY Rs. 1102.1 Cr, QoQ Rs. 1390 Cr
Provision came at Rs. 11.1 Cr vs expectation of Rs. 42.9 Cr, YoY Rs. 4.8 Cr, QoQ Rs. 58.5 Cr
PAT came at Rs. 995.7 Cr vs expectation of Rs. 1124.5 Cr, YoY Rs. 815.1 Cr, QoQ Rs. 991.4 Cr
Quarter EPS is Rs. 24.8
Share is trading at P/E of 12.1x FY22E EPS & 3.5x trailing P/BV
(Nirmal Bang Retail Research)
*Result is in-line with expectations*
Asset quality details are not yet declared
NII came at Rs. 1872.6 Cr vs expectation of Rs. 1887.3 Cr, YoY Rs. 1630.3 Cr, QoQ Rs. 1819.3 Cr
PBP came at Rs. 1360.8 Cr vs expectation of Rs. 1382.6 Cr, YoY Rs. 1102.1 Cr, QoQ Rs. 1390 Cr
Provision came at Rs. 11.1 Cr vs expectation of Rs. 42.9 Cr, YoY Rs. 4.8 Cr, QoQ Rs. 58.5 Cr
PAT came at Rs. 995.7 Cr vs expectation of Rs. 1124.5 Cr, YoY Rs. 815.1 Cr, QoQ Rs. 991.4 Cr
Quarter EPS is Rs. 24.8
Share is trading at P/E of 12.1x FY22E EPS & 3.5x trailing P/BV
*Lupin* has announced that USFDA has accepted its Biologics License Application or its proposed biosimilar to Neulasta® (pegfilgrastim, annual sales $3.7bn). *Positive*
*PVR Ltd.* | *CMP* Rs. 1310 | *M Cap* Rs. 7965 Cr | *52 W H/L* 1592/759
(Nirmal Bang Retail Research)
*Result is inline*
Revenue from Operations came at Rs. 181.5 Cr (299.7% QoQ, -71.9% YoY) vs expectation of Rs. 161.8 Cr, QoQ Rs. 45.4 Cr, YoY Rs. 645.1 Cr
EBIDTA came at Rs. -56.7 Cr (-27.4% QoQ, -132.9% YoY) vs expectation of Rs. -43.5 Cr, QoQ Rs. -78.1 Cr, YoY Rs. 172.7 Cr
EBITDA Margin came at -31.3% vs expectation of -26.9%, QoQ -172.1%, YoY 26.8%
Adj. PAT came at Rs. -289.1 Cr vs expectation of Rs. -173.6 Cr, QoQ Rs. -49.1 Cr, YoY Rs. -74.5 Cr
Quarter EPS is Rs. -47.6
Share is trading at P/E of 155.4x FY22E EPS
(Nirmal Bang Retail Research)
*Result is inline*
Revenue from Operations came at Rs. 181.5 Cr (299.7% QoQ, -71.9% YoY) vs expectation of Rs. 161.8 Cr, QoQ Rs. 45.4 Cr, YoY Rs. 645.1 Cr
EBIDTA came at Rs. -56.7 Cr (-27.4% QoQ, -132.9% YoY) vs expectation of Rs. -43.5 Cr, QoQ Rs. -78.1 Cr, YoY Rs. 172.7 Cr
EBITDA Margin came at -31.3% vs expectation of -26.9%, QoQ -172.1%, YoY 26.8%
Adj. PAT came at Rs. -289.1 Cr vs expectation of Rs. -173.6 Cr, QoQ Rs. -49.1 Cr, YoY Rs. -74.5 Cr
Quarter EPS is Rs. -47.6
Share is trading at P/E of 155.4x FY22E EPS
Follow this link to join my WhatsApp group: https://chat.whatsapp.com/LYY276dyprVJpKMQgxRm2q
Important Note
Since last 2 months are quantity of calls have been more because Smallcaps and Midcaps are in flavor and we dont want any of our members to feel left out. We are trying are best to give all types of calls to our members. Trying to satisfy all needs and demands brought up by members, but this rally will eventually fizzle out soon in few months. SO keep booking profits and keep your targets realistic. We wont be getting 20 - 30% moves just like we get now so quickly and easily in future. Having proper trading system and proper guidance is very important.
We at MARKET WIZARD will always working with same commitment and integrity for all.
Thanks and Regards,
TEAM MARKET WIZARD
Since last 2 months are quantity of calls have been more because Smallcaps and Midcaps are in flavor and we dont want any of our members to feel left out. We are trying are best to give all types of calls to our members. Trying to satisfy all needs and demands brought up by members, but this rally will eventually fizzle out soon in few months. SO keep booking profits and keep your targets realistic. We wont be getting 20 - 30% moves just like we get now so quickly and easily in future. Having proper trading system and proper guidance is very important.
We at MARKET WIZARD will always working with same commitment and integrity for all.
Thanks and Regards,
TEAM MARKET WIZARD